In this work, we demonstrated that single agent treatment with the selective BCL2 inhibitors Venetoclax and WEHI-539 at therapeutically relevant concentrations decreases mitochondrial ATP production in breast cancer cells in the absence of cell death. The gene discussed is BCL2; the disease is breast cancer.